menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Jiaotong University Affiliated Sixth People's Hospital","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Shanghai Jiaotong University Affiliated Sixth People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Jiaotong University Affiliated Sixth People's Hospital \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Jiaotong University Affiliated Sixth People's Hospital \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Beijing Life Oasis Public Service Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chinese SLE Treatment And Research Group \/ Beijing Life Oasis Public Service Center","highestDevelopmentStatusID":"11","companyTruncated":"Chinese SLE Treatment And Research Group \/ Beijing Life Oasis Public Service Center"},{"orgOrder":0,"company":"The Affiliated Hospital of Qingdao University","sponsor":"Wenzhou Haihe Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"The Affiliated Hospital of Qingdao University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Affiliated Hospital of Qingdao University \/ Wenzhou Haihe Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"The Affiliated Hospital of Qingdao University \/ Wenzhou Haihe Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Xi\u2019an Honghui Hospital","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Xi\u2019an Honghui Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xi\u2019an Honghui Hospital \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Xi\u2019an Honghui Hospital \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Towa Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chugai Pharmaceutical \/ Towa Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chugai Pharmaceutical \/ Towa Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Termination","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taisho Pharmaceutical \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Taisho Pharmaceutical \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"e-GLORIA Protocol Review Committee","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"e-GLORIA Protocol Review Committee","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"e-GLORIA Protocol Review Committee \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"e-GLORIA Protocol Review Committee \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Eldecalcitol

    Menu

    Eldecalcitol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Towa Pharmaceutical

                            Japan
                            CPhI WW Frankfurt
                            Booth #9.2A94
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothTowa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Towa Gets Approval for Generic Edirol, Osteoporosis Drug from Chugai Pharma

                            Details : Edirol-Generic (eldecalcitol) is a vitamin D receptor agonist, which is indicated for the treatment of osteoporosis.

                            Product Name : Edirol-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 03, 2021

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Towa Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chinese SLE Treatment And Research Group

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            Chinese SLE Treatment And Research Group

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Beijing Life Oasis Public Service Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study on the Prevention and Treatment of GIOP With Eldecalcitol

                            Details : Eldecalcitol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 25, 2024

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Beijing Life Oasis Public Service Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shanghai Jiaotong University Affiliated Sixth People's Hospital

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            Shanghai Jiaotong University Affiliated Sixth People's Hospital

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis

                            Details : Eldecalcitol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Bone Diseases, Metabolic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 13, 2023

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Xi’an Honghui Hospital

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            Xi’an Honghui Hospital

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteopo...

                            Details : Eldecalcitol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoporosis, Postmenopausal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 01, 2023

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chugai Pharmaceutical

                            Japan arrow
                            SupplySide West
                            Not Confirmed

                            Chugai Pharmaceutical

                            Japan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Towa Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment

                            Details : Edirol® Tablets 0.5 µg/0.75 µg (generic name: eldecalcitol, hereafter, Edirol Tablet) for an osteoporosis treatment (an active vitamin D3 preparation). Chugai manufactures Edirol Tablet and supplies to Towa.

                            Product Name : Edirol

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 09, 2022

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Towa Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Chugai Pharmaceutical

                            Japan arrow
                            SupplySide West
                            Not Confirmed

                            Chugai Pharmaceutical

                            Japan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Towa Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chugai Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tablet

                            Details : Edirol (eldecalcitol), is an active vitamin D3 derivative created based on Chugai’s long-standing vitamin D research. Chugai takes responsibilities as a holder of the approval, Towa will be responsible for marketing and providing information on use of ...

                            Product Name : Edirol

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 15, 2022

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Towa Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            The Affiliated Hospital of Qingdao University

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            The Affiliated Hospital of Qingdao University

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Wenzhou Haihe Pharmaceutical Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Eldecalcitol Soft Capsule in Healthy Chinese Subjects

                            Details : Eldecalcitol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2022

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Wenzhou Haihe Pharmaceutical Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Taisho Pharmaceutical

                            Japan arrow
                            SupplySide West
                            Not Confirmed

                            Taisho Pharmaceutical

                            Japan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Chugai Pharma, Taisho Pharma Terminate Co-Marketing Agreement for Edirol to Treat Osteoporosis

                            Details : Chugai Pharmaceutical and Taisho Pharmaceutical announced termination of the agreement between both companies regarding co-marketing of Edirol® Capsules 0.5 µg and 0.75 µg, a treatment for osteoporosis for which Chugai has a marketing authorization.

                            Product Name : Edirol

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 22, 2021

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Chugai Pharmaceutical

                            Japan arrow
                            SupplySide West
                            Not Confirmed

                            Chugai Pharmaceutical

                            Japan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chugai's Osteoporosis Agent Edirol Obtains Regulatory Approval in China

                            Details : Chugai has obtained regulatory approval for eldecalcitol (product name: Edirol®), an active vitamin D3 derivative created by Chugai from the China National Medical Products Administration (NMPA).

                            Product Name : Edirol

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 18, 2020

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            e-GLORIA Protocol Review Committee

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            e-GLORIA Protocol Review Committee

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol

                            Details : Eldecalcitol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Osteoporosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 01, 2013

                            Lead Product(s) : Eldecalcitol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth